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Abstract
Background: Epstein-Barr virus (EBV) and cytomegalovirus (CMV) infection are 
common in early childhood. CMV infection favours a T-helper-1 and EBV infection a 
T-helper-2 cell response, possibly leading to disbalanced T-helper cell response, and 
subsequent risk of asthma or atopy.
Objective: To study the associations of EBV and CMV with lung function, asthma and 
inhalant allergic sensitization at school age.
Methods: This study among 3546 children was embedded in a population-based pro-
spective cohort. At age 6 years, serum IgG levels against EBV and CMV were meas-
ured by ELISA. At age 10 years, lung function was measured by spirometry, asthma 
by questionnaire and inhalant allergic sensitization by skin prick test.
Results: Unadjusted models showed that seropositivity for EBV was associated with 
a higher FEV1 and FEF75 (Z-score difference (95% CI): 0.09 (0.02, 0.16) and 0.09 (0.02, 
0.15)), while seropositivity for CMV was not. Specific combinations of viruses showed 
that seropositivity for EBV was only associated with FEV1 and FEF75 in the presence 
of seropositivity for CMV (0.12 (0.04, 0.20)) and 0.08 (0.01, 0.15)). Seropositivity 
for CMV in the absence of seropositivity for EBV was associated with an increased 
risk of inhalant allergic sensitization (OR (95% CI): 1.31 (1.02, 1.68)). All effect esti-
mates attenuated into non-significant mainly after adjustment for child's ethnicity. 
Seropositivity for EBV or CMV was not associated with asthma.
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1  | INTRODUC TION
Infectious diseases in early life are suggested to influence the risk of 
lower lung function and asthma in later childhood and adulthood.1-4 
Epstein-Barr virus (EBV) and cytomegalovirus (CMV) are herpesviri-
dae that are commonly present. Between 60% and 90% of the adults 
are seropositive with the peak of infections occurring in childhood, 
and result in life-long viral persistence.5-7 Successful viral suppres-
sion is dependent on expanded T cell memory population. Both vi-
ruses primarily affect immune cells, but do not have the same effects. 
EBV favours a T-helper-2 cell-mediated response and mostly seems 
to affect B-cells.8,9 CMV has a T-helper-1 cell-mediated response, 
and impacts on T cell and natural killer (NK) cell differentation.10,11 
Moreover, both viruses drive memory T cell expansions in young 
children.12,13 Therefore, infections with these viruses could lead to a 
disbalance in immune responses, specifically T-helper cell-mediated 
responses, and subsequently an increased risk of asthma.2-4 A pro-
spective cohort study demonstrated that EBV coinfection enhances 
immune maturation driven by CVM.14 Two other studies found that 
children with EBV had a reduced antibody response to measles or ru-
bella vaccination, while children co-infected with CMV had not.15,16 
This further suggests that these herpesviridae might have interact-
ing effects on the immune system. Results from previous studies on 
the associations of seropositivity for EBV or CMV with asthma and 
atopy are inconsistent.2,4,17 This might be explained by the examina-
tion of EBV or CMV solely, while co-infections of these viruses might 
be more important given their difference in immune response.3,4 
This is supported by a cohort study that demonstrated that CMV 
in the absence of EBV at the age of 4 years was associated with an 
increased risk of specific IgE of inhalant allergens, or inhalant and 
food allergens combined, but not asthma.3 Studies on associations 
of EBV or CMV with atopic outcomes at older ages in childhood, 
including more objective respiratory measures such as lung function, 
are lacking.
Therefore, we examined the associations of childhood EBV or 
CMV, solely and in combination, with school-age lung function, 
Conclusions and Clinical Relevance: Associations of EBV and CMV infections in early 
childhood with school-age lung function and inhalant allergic sensitization are ex-
plained by ethnicity, or sociodemographic and lifestyle-related factors.
K E Y W O R D S
asthma, child, epidemiology, herpesviridae, respiratory function test
F I G U R E  1   Flow chart of participants 
included for analysis
Children with participation at age 10 
years
n = 7393
Children with information on 
respiratory health available
n = 3546
Epstein-Barr virus n = 3546
Cytomegalovirus n = 3546
Lung function n = 3164
Asthma n = 2985
Inhalant allergic n = 2581
sensitization
Children with information on Epstein-
Barr virus and Cytomegalovirus
n = 4030
n = 484
No information on respiratory 
health at age 10 years
n = 3894
Twins (n = 185) and no information 
on Epstein-Barr and 
Cytomegalovirus infections at age 
6 years (n = 3178)
data collection and analysis, interpretation 
of data, writing of this report or the decision 
to submit the article for publication.
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asthma and inhalant allergic sensitization in a population-based pro-
spective cohort study among 3546 children.
2  | METHODS
2.1 | Design
This study was embedded in the Generation R Study, a population-
based prospective cohort from early fetal life onwards in Rotterdam, 
the Netherlands.18 The study is designed to identify early environ-
mental and genetic causes and causal pathways leading to normal 
and abnormal growth, development and health from fetal life to 
childhood and young adulthood. In total, 9778 mothers with a de-
livery date from April 2002 until January 2006 were enrolled in the 
study. Response at baseline was 61%, and general follow-up rates 
until the age of 10 years were around 80%. The study has been 
approved by the Medical Ethical Committee of the Erasmus MC, 
University Medical Center Rotterdam, Rotterdam, The Netherlands 
(MEC-2012-165). Written informed consent was obtained from par-
ents or legal representatives of all children. Of the 7393 children 
with participation at age 10 years, we excluded twins (n = 185), chil-
dren without information on EBV or CMV (n = 3709), and without 
information on respiratory health (n = 484), which left 3546 children 
for the current analysis (Figure 1).
2.2 | EBV and CMV
Venous blood samples were obtained by antecubital venipuncture 
during a visit at the research centre (median age 6.0 years, 5%-
95% range 5.7-7.2 years). The response rate for serum samples was 
69%. Samples were stored for a maximum of 4 hours at 4°C, and 
transported twice daily for further processing and storage. Serum 
samples were analysed using ELISA for IgG antibodies against EBV 
capsid antigen (native mixture of several viral capsid antigens) and 
CMV (purified native antigens strain “AD169”) (EUROIMMUN). As 
described earlier, seropositivity was defined as a sample-treshold 
ratio above 0.8 for EBV and 0.6 for CMV.12 The presence of seropos-
itivity for the viruses was further combined into neither, EBV only, 
CMV only, and both EBV and CMV.
2.3 | Respiratory health
We performed spirometry according to the American Thoracic 
Society (ATS) and European Respiratory Society (ERS) recommenda-
tions during a visit at the research centre (median age 9.7 years, 5%-
95% range 9.5-10.3 years). Lung function measures included Forced 
Expiratory Volume in 1 second (FEV1), Forced Vital Capacity (FVC), 
FEV1/FVC and Forced Expiratory Flow after exhaling 75% of FVC 
(FEF75) and were converted into sex-, height-, age- and ethnicity-
adjusted z-scores according to the Global Lung Initiative reference 
data.19 Children (n = 239) with a >5%, instead of ≤5%, deviation in 
FEV1 and FVC, and at least one blow with adequate reach and du-
ration of plateau according to ATS/ERS criteria were also included. 
The effect estimates for the associations did not differ when we in- 
or excluded those children.20,21 Information on asthma medication 
use in the past 12 months was obtained during the research centre 
visit. Asthma was defined as ever diagnosis of asthma, obtained by 
questionnaire at the age 10 years, with either wheezing or asthma 
medication use in the past 12 months. Questions on wheezing 
and asthma were based on the International Study on Asthma and 
Allergy in Childhood (ISAAC) Questionnaire obtained by post (“Has 
your child suffered from attacks of wheezing in the chest in the 
past 12 months?” (no/yes, <4 attacks/yes ≥4 attacks) and “Has your 
child ever had asthma diagnosed by a doctor?” (no/yes <3 years/yes 
3-6 years/yes >6 years of age)).22 Information on medication use was 
obtained by a short questionnaire during the visit at the research 
centre (“Did your child receive any prescribed medication in the past 
12 months for complaints of the airways, lungs, allergy or skin? If 
yes, which medication was this?” (no/yes: <name prescribed drug>)). 
Median time between the questionnaire and visit to the research 
centre was 1.4 (5%-95% range −6 to 12) weeks. As described earlier, 
inhalant allergic sensitization at the age of 10 years was measured 
by skin prick test (SPT), using the scanned area method.23 Inhalant 
allergens included house-dust mite, 5-grass mixture, birch, cat and 
dog (ALK-Albelló BV). Children were considered to have inhalant al-
lergic sensitization when they were sensitized to at least one inhal-
ant allergen.
2.4 | Covariates
At enrolment, information on maternal age, ever history of asthma 
and atopy (no/yes), educational level (low or middle/high), body 
mass index, parity and current pet keeping (no/yes) was obtained by 
questionnaires during pregnancy. Information on maternal smoking 
during pregnancy was obtained in early, mid and late pregnancy by 
questionnaires, and combined into no smoking or quitting in early 
pregnancy/continued smoking. Psychological distress during mid-
pregnancy was measured by the Brief Symptom inventory.24 Child's 
gestational age at birth and birth weight were obtained from midwife 
and hospital records at birth. Child's ethnicity was based on country 
of birth of the parents from parental questionnaires at enrolment, 
and combined (European/non-European). Questionnaires in the first 
year of life provided information on ever breastfeeding (no/yes) and 
daycare attendance in the first year of life (no/yes).
2.5 | Statistical analysis
First, we compared characteristics of mothers and children in-
cluded in the study to those lost to follow-up. Next, we studied the 
associations of both EBV and CMV solely and combined (neither, 
EBV only, CMV only or both EBV and CMV) with lung function, 
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and asthma and inhalant allergic sensitization by using linear and 
logistic regression models, respectively. All models were adjusted 
for confounders, which were selected from literature, and were 
associated with the exposure and the outcome, or changed the 
effect estimates of univariate analyses with 10% or more when 
added to the crude model. Confounders were grouped into so-
ciodemographic and health-related factors (maternal age, history 
of asthma and atopy, educational level, parity and psychological 
distress during pregnancy), lifestyle-related factors (maternal 
body mass index, smoking during pregnancy and pet keeping, and 
child's birth weight adjusted for gestational age, breastfeeding and 
daycare attendance) and child's ethnicity. Models were adjusted 
for each group of confounders separately, and finally for all groups 
of confounders. The percentage of missing data in confounders 
was between 1.7% and 24.8%, except for daycare attendance 
(37.9%). Missing data were imputed by multiple imputation using 
chained equations to select the most likely value for a missing re-
sponse, creating ten new datasets. Since we observed no major 
differences in the magnitude or direction of the effect estimates 
between analyses with imputed missing data and complete cases 
only, we only present the results based on imputed datasets. All 
measures of association are presented as odds ratios (OR) or Z-
score differences and their corresponding 95% confidence in-
tervals (95% CI). Statistical analyses were performed using SPSS 
version 25.0 for Windows software (IBM Corp).
3  | RESULTS
3.1 | Subject characteristics
Characteristics of children and their mothers are presented in 
Table 1. At the age of 6 years, 50.4% (n = 1787) of the children 
were seropositive for EBV, and 41.5% (n = 1470) for CMV. When 
we combined the viruses, 32.6% (n = 1155) of the children was 
seropositive for none of the viruses, 26.0% (n = 921) for EBV only, 
17.0% (n = 604) for CMV only and 24.4% (n = 866) for both. The 
prevalence of current asthma at the age of 10 years was 5.8% 
(n = 172), and of inhalant allergic sensitization 31.7% (n = 818). 
Children not included in the analysis had mothers who were 
younger and lower educated, had a higher body mass index and 
had more psychological distress during pregnancy. Children were 
more often of non-European ethnicity, had a lower gestational age 
and birth weight, and were more likely to be seropositive for EBV, 
but not CMV (Table S1).
3.2 | EBV, CMV and respiratory health
In the unadjusted analyses, EBV, but not CMV, was associated with 
a higher FEV1 and FEF75 (Z-score difference (95% confidence inter-
val): 0.09 (0.02, 0.16) and 0.09 (0.02, 0.15), respectively) (Table 2). 
Combinations of seropositivity for the viruses showed that only 
seropositivity for EBV in the presence of seropositivity for CMV 
was associated with higher FEV1, FVC and FEF75 (Z-score differ-
ence (95% CI): 0.12 (0.04, 0.20), 0.10 (0.02, 0.17) and 0.08 (0.01, 
0.15), respectively)). Seropositivity for EBV or CMV, or combinations 
of seropositivity for the viruses were not associated with asthma. 
Seropositivity for EBV or CMV solely were not associated with in-
halant allergic sensitization. Combinations of seropositivity for the 
viruses demonstrated that only seropositivity for CMV in the ab-
sence of seropositivity for EBV was associated with an increased 
risk of inhalant allergic sensitization (OR (95% CI): 1.29 (1.01, 1.65). 
After adjustment for confounders, all effect estimates attenuated 
TA B L E  1   Characteristics of children and their mothers
 n = 3546
Maternal characteristics
Age (y) 31.2 (4.9)
History of asthma or atopy, yes (%) 36.2 (1285)
Educational level, low/middle (%) 50.3 (1751)
Body mass index at intake (kg/m2) 24.6 (4.2)
Parity, nulliparous (%) 55.5 (1967)
Psychological distress during pregnancya 0.17 (0.00, 0.93)
Smoking during pregnancy, yes (%) 14.4 (512)
Pet keeping, yes (%) 36.4 (1290)
Child's characteristics
Female sex (%) 48.8 (1729)
Gestational age at birth (wks)a 40.1 (37.0, 42.0)
Birth weight (g) 3447 (546)
Ethnicity, European (%) 67.7 (2399)
Ever breastfeeding, yes (%) 91.7 (3252)
Day care attendance 1st y, yes (%) 55.4 (1966)
EBV IgG at 6 y, positive (%) 50.4 (1787)
CMV IgG at 6 y, positive (%) 41.5 (1470)
Combination of infections (%)
Neither 32.6 (1155)
EBV only 26.0 (921)
CMV only 17.0 (604)
Both 24.4 (866)
Lung function measures
FEV1 (L) 2.02 (0.30)
FVC (L) 2.34 (0.36)
FEV1/FVC (%) 87.0 (5.6)
FEF75 (L/s) 1.15 (0.35)
Asthma, yes (%) 5.8 (172)
Inhalant allergic sensitization, yes (%) 31.7 (818)
Note: Values are means (SD), valid percentages (absolute numbers) or 
amedians (5-95th percentiles). Values are based on imputed data. Data 
was missing and not imputed for lung function measures (n = 382), 
asthma (n = 561), and inhalant allergic sensitization (n = 965).
Abbreviations: CMV, Cytomegalovirus; EBV, Epstein-Barr virus; 
FEF75, forced expiratory flow after exhaling 75% of FVC; FEV1, forced 
expiratory volume in the first second; FVC, forced vital capacity.
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into non-significant (Table 3 and Table S2). The associations of the 
viruses with lung function were mainly explained by ethnicity of the 
child, while the association with inhalant allergic sensitization was 
explained by sociodemographic and health-related factors, lifestyle-
related factors and ethnicity.
4  | DISCUSSION
4.1 | Principal findings
In this population-based prospective cohort study, we observed 
that seropositivity for EBV in early childhood was associated with 
higher lung function at school age. This association was driven by 
seropositivity for EBV in the presence of seropositivity for CMV. 
Seropositivity for EBV or CMV were not associated with asthma. 
Only seropositivity for CMV in the absence of seropositivity for EBV 
was associated with an increased risk of inhalant allergic sensitiza-
tion. The associations of the viruses with respiratory health were 
fully explained by ethnicity, or sociodemographic and health-related 
factors, and lifestyle-related factors.
4.2 | Comparison with previous studies
We observed that EBV and CMV in early childhood were not inde-
pendently associated with respiratory health in later childhood life. 
To our knowledge, this is the first study to associate EBV or CMV 
with lung function measures, and respiratory health later in child-
hood. A cross-sectional analysis within a prospective cohort study 
demonstrated that seropositivity for EBV was not associated with 
asthma or allergic sensitization at age 4 years.2 Additionally, they 
demonstrated that CMV solely was not associated with asthma, al-
lergy or allergic sensitization.3 Two studies have shown that CMV 
in the absence of EBV was associated with an increased risk of al-
lergic sensitization measured by IgE, at either 2 or 4 years of age.3,4 
Our result that CMV in the absence of EBV is associated with an 
increased risk of inhalant allergic sensitization is in line with these 
findings. However, we additionally found that these associations 
were explained by confounding factors. The composition of the 
study population, difference in confounders or measurement of al-
lergic sensitization by skin prick test as opposed to specific serum 
IgE might explain this difference in results. We could not replicate 
the finding that EBV was associated with a decreased risk of aller-
gic sensitization.4 Similar to previous findings, we showed that EBV 
and CMV, solely or combined, were not associated with asthma.2,3 A 
case-control study comparing CMV DNA between adults with and 
without asthma, demonstrated that those with asthma were more 
likely to be positive for CMV DNA.25 Additionally, the number of 
CMV copies was higher in elderly, defined as age above 65 years, 
with asthma as compared to elderly without asthma. The number 
of CMV copies was not different in non-elderly with and without 
asthma. The number of CMV copies was also higher in elderly with 
asthma as compared to non-elderly with asthma. This suggests that 
age might be of importance, although due to the cross-sectional na-
ture of the study it was not possible to disentangle the direction of 
the effect. Further studies are needed to examine the role of age of 
the child at virus infection, and the role of ethnicity and other con-
founding factors in the association of EBV and CMV with respiratory 
health across the life course.
4.3 | Strengths and limitations
This study was embedded in a population-based cohort study, and 
detailed measurements of respiratory health, and information on 
numerous confounders are important strengths. Some limitations 
should be discussed. First, prospective cohort studies have sug-
gested that early infection with herpesviridae might lead to a de-
creased risk of atopy, measured by SPT or IgE, and late infections 
to an increased risk.17,26 However, we measured seropositivity for 
IgG only and were not able to determine age of seroconversion. 
Additionally, children in our study with an infection occurring be-
tween 6 and 10 years of age would be classified as seronegative, 
leading to dilution of the effect. Second, it has been suggested that 
immune responses might differ between asymptomatic and mono-
nucleosis-like infections. Unfortunately, we did not have detailed 
information on the clinical course of the herpesviridae infections. 
However, given that we study a childhood cohort with infections 
before 6 years of age, these infections are most likely mild or asymp-
tomatic.15 Third, information on asthma was obtained by question-
naire, which might have led to misclassification although a validated 
questionnaire was used to minimize bias. Last, selection bias due 
to loss to follow-up might have occurred. Most importantly, those 
lost to follow-up were more likely to be of non-European ethnicity, 
and more likely to be seropositive for EBV. This might have led to 
either an over- or underestimation of the effect, if the associations 
of those lost to follow-up with respiratory health would be differ-
ent from those included in the study. This is unlikely, but cannot be 
excluded.27,28
4.4 | Underlying mechanisms
Some evidence on possible underlying mechanisms for the as-
sociations of herpesviridae with the immune and pulmonary 
system are provided in murine studies. One murine study dem-
onstrated that mice infected in early life with murid herpesvirus 
4, the murine equivalent of EBV, were protected against house-
dust mite–induced airway allergy, compared to uninfected mice.29 
These infected mice had a reduced peribronchial infiltration by 
inflammatory cells, and lower numbers of eosinophils and in-
terleukin-4. 5 and 6 in broncho-alveolar fluid. Additionally, the 
T-helper-2 polarization of house-dust mite–specific T cells, but 
not T-helper-1 polarization, was suggested to be impaired among 
infected mice. Another murine study found that after infection 
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with murid herpesvirus 4, or murine cytomegalovirus, more secre-
tion of T-helper-1 cytokines was present, which might inhibit the 
T-helper-2 pathway.30 In our study, we found that mainly ethnic-
ity explained the association of EBV with a higher lung function. 
The association of CMV in the absence of EBV with inhalant al-
lergic sensitization was explained by ethnicity, and also sociode-
mographic and health-related, and lifestyle factors. A previous 
study within our cohort demonstrated that non-Dutch children 
were more likely to be seropositive for EBV and CMV.31 These 
ethnic differences were partly explained by socio-economic fac-
tors and factors related to crowding for EBV, but not for CMV. 
Other studies also demonstrated an association of ethnicity with 
the prevalence of herpesviridae, although the role of other factors 
explaining the association such as socio-economic or lifestyle-re-
lated factors in these studies were less prominent.32,33 Another 
prospective cohort study demonstrated that maternal age was 
associated with time to infection for EBV and CMV, regardless 
of other factors such as daycare and siblings.34 Additionally, they 
demonstrated that CMV is often acquired earlier than EBV, which 
might be explained by the immune response after CMV infection. 
Our findings suggest that there might be no causal association 
of EBV and CMV with respiratory health, but that ethnicity and 
possible other confounding factors are the underlying explaining 
mechanisms.
5  | CONCLUSION
Seropositivity for EBV and CMV at the age of 6 years were as-
sociated with a higher lung function and inhalant allergic sensiti-
zation, respectively, but not asthma at school age. However, the 
association of seropositivity for EBV with school-age lung func-
tion was explained by child's ethnicity, while the association of se-
ropositivity for CMV in the absence of EBV with inhalant allergic 
sensitization was additionally explained by sociodemographic and 
health-related, and lifestyle-related factors. Future studies should 
focus on the role of age of the child at primary infection, specifi-
cally in relation to lung function and asthma, and the possible ex-
plaining role of ethnicity.
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